The development of biomarkers that can measure responsiveness to treatments and those that assess the risk of developing into full-fledged disease are critical clinical endpoints.

Rockville, US, 2018-Aug-10 — /EPR Network/ — Tuberculosis (TB) biomarkers occupy a central role in the disease characterization, infection and risk assessment, rapid diagnosis, and ultimately [read full press release…]